Stereotactic Ablative Radiation Therapy for Kidney Cancer

Recruiting in Palo Alto (17 mi)

Overseen byRaquibul Hannan, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of Texas Southwestern Medical Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The goal of this phase II clinical trial is to evaluate the efficacy of the completely non-invasive treatment option of stereotactic radiation therapy for the treatment of biopsy proven and growing small renal tumors.

Research Team

Raquibul Hannan, MD, PhD

Principal Investigator

UTSW

Eligibility Criteria

This trial is for adults with small kidney tumors (≤5cm) that have been biopsy-proven and shown growth. Participants must be able to undergo MRI or CT scans, use effective contraception if of childbearing potential, and not be pregnant. Those who've had prior treatments for the renal mass or have metastatic disease (with exceptions) can't join.

Inclusion Criteria

I agree to use effective birth control or abstain from sex during the study.

My kidney tumor was confirmed by a biopsy.

My kidney cancer includes all types, even oncocytoma.

See 7 more

Exclusion Criteria

I have undergone treatments like RFA or cryoablation for my kidney tumor.

I have had radiation therapy to my abdomen before.

I am not pregnant nor planning to become pregnant during the treatment.

See 1 more

Treatment Details

Interventions

Stereotactic Ablative Radiation Therapy (Radiation Therapy)

Trial OverviewThe study is testing Stereotactic Ablative Radiation Therapy (SABR), a non-invasive treatment targeting small growing renal tumors. It's a phase II trial aiming to assess how well this therapy works in eliminating cancer cells without surgery.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Stereotactic Ablative Radiation TherapyExperimental Treatment1 Intervention

Stereotactic Ablative Radiation Therapy (SABR)